

Financial Information for the 1st Quarter of Fiscal Year Ending March 31, 2022

As of August 4, 2021

Mitsubishi Tanabe Pharma Corporation



Mitsubishi Tanabe Pharma

(Note about forward-looking information)

The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties. It contains information about pharmaceuticals including products under development, but is not intended for advertising or medical advice.

Table of Contents

1	Summary of Financial Results for the 1st Quarter of FY2021 Ending March 31, 2022 and Forecasts for FY2021		
	1. Summary of Financial Results for the 1st Quarter of FY2021	...	2
	2. Summary of Forecasts for FY2021	...	2
2	Consolidated Financial Indicators for the 1st Quarter of FY2021		
	1. Profit and Loss	...	3
	(1) Profit and Loss	...	3
	(2) Sales Revenue of Main Products	...	3
	2. Financial Statement	...	4
	(1) Balance Sheet	...	4
	(2) Cash Flow Statement	...	4
	(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems	...	4
	(4) Depreciation and Amortization Costs	...	4
3	Forecasts for FY2021		
	(1) Consolidated Forecasts of Profit and Loss	...	5
	(2) Sales Revenue Forecasts for Main Products	...	5
4	Quarterly Trend		
	(1) Profit and Loss	...	6
	(2) Sales Revenue of Main Products	...	7
5	Five-Year Financial Data		
	(1) Profit and Loss (2) Balance Sheet (3) Other Financial Data	...	8
	(4) Number of Employees	...	8
6	State of New Product Development (As of July 26, 2021)		
	(1) Central nervous system (2) Immuno-inflammation	...	9
	(3) Vaccines (4) Others	...	10
	Changes Since Previous Announcement	...	11

1 Summary of Financial Results for the 1st Quarter of FY2021 Ending March 31, 2022 and Forecasts for FY2021

(Amounts less than ¥100 million are rounded)

<Regarding GILENYA Royalty>

As Mitsubishi Tanabe Pharma Corporation (hereinafter, "MTPC") announced on April 24, 2019 in the "Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2019", MTPC is currently in the arbitration proceedings with Novartis Pharma AG (hereinafter "Novartis"), and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts, which correspond to the clauses in the 1997 License Agreement of which Novartis has protested the validity, as our revenue because such payments do not satisfy one of the requirements under IFRS15, i.e., "Revenue under contract with customers". During the period of the arbitration proceedings, MTPC will continue the same accounting practice as MTPC did in fiscal year 2018. For fiscal year 2020, the forecast is prepared on the assumption that the arbitration procedure to continue. MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration. As for the amounts among the GILENYA Royalty amounts which will not be recognized as sales revenue, those will be recognized as revenue at the end of the arbitration, depending on the outcome of the arbitration.

1. Summary of Financial Results for the 1st Quarter of FY2021

[Billion yen]

Revenue	95.4	Y-on-Y	3.6	3.9 %
Domestic	77.0	Y-on-Y	1.2	1.6 %
Overseas	18.4	Y-on-Y	2.4	14.7 %

• Domestic ethical drugs sales increased by 1.7% to ¥74.5 bn, due to increase of STELARA which was additionally approved for the treatment for ulcerative colitis in March 2020, SIMPONI for Rheumatoid arthritis (RA) treatment etc. and CANAGLU for type 2 diabetes mellitus treatment, despite NHI price revision conducted in April 2021 and expansion of generic drugs.

• Sales from overseas increased by 13.8% to ¥14.4 bn, due to increase of Radicava for Amyotrophic Lateral Sclerosis treatment and other products.

• Royalty revenue, etc. increased by 15.7% to ¥4.3 bn.

[Billion yen]

Core Operating Profit*	5.8	Y-on-Y	(3.8)	(39.2 %)
------------------------	-----	--------	-------	----------

Core operating profit decreased due to higher sales expenses in the relaxation of voluntary restrictions on activities under COVID-19 spread and increase of R&D expenses on COVID-19 vaccine, etc. despite increase of sales revenue.

* With adoption of IFRS, the Company, its subsidiaries and its affiliates (collectively, "the Group") has introduced "core operating profit" as a major profit index to demonstrate its recurring profitability and positioned as an important indicator of business management, etc. "Core operating profit" is a profit excluding the income and loss recorded by non-recurring items specified by the Group (hereinafter "non-recurring items") from operating profit. The Company assumes gain or loss associated with a business transfer, restructuring loss, impairment losses on intangible assets associated with products and others as non-recurring items.

[Billion yen]

Operating Profit	5.8	Y-on-Y	(11.9)	(67.1 %)
Net Income Attributable to owners of the Company	3.1	Y-on-Y	(8.4)	(73.4 %)

2. Summary of Forecasts for FY2021

[Billion yen]

Revenue	407.5	Y-on-Y	29.7	7.9 %
Core Operating Profit	26.0	Y-on-Y	5.0	23.6 %
Operating Profit	30.0	Y-on-Y	88.5	-
Net Income Attributable to owners of the Company	17.5	Y-on-Y	64.4	-

Forecasts remain unchanged from those announced on May 12, 2021.

2 Consolidated Financial Indicators for the 1st Quarter of FY2021

(Amounts less than ¥ 100 million are rounded)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	Q1 FY2021	Comparison to previous year			Comparison to Forecasts		Notes [Y-on-Y comparison]
		Q1 FY2020	Increase (decrease)	Change %	Forecasts*1	Change %	
Revenue	95.4	91.8	3.6	3.9	407.5	23.4	Refer to "(2) Sales Revenue of Main Products"
Domestic	77.0	75.7	1.2	1.6	296.1	26.0	
Overseas	18.4	16.1	2.4	14.7	111.4	16.5	
Overseas sales ratio	19.3%	17.5%			27.3%		
Cost of sales	47.6	45.6	2.1	4.5	192.5	24.7	Deteriorated by NHI price revision, etc.
Sales cost ratio	49.9%	49.7%			47.2%		
Gross profit	47.7	46.2	1.5	3.3	215.0	22.2	
SG&A expenses, etc.	41.9	36.6	5.3	14.5	189.0	22.2	
R&D expenses	18.8	15.3	3.5	22.9	85.0	22.1	Due mainly to increase of clinical trials costs of global products
Core operating profit	5.8	9.6	(3.8)	(39.2)	26.0	22.4	
Non-recurring items ²	(0.0)	8.1	(8.1)	-	4.0	-	
Operating profit	5.8	17.7	(11.9)	(67.1)	30.0	19.3	
Net profit attributable to owners of the Company	3.1	11.5	(8.4)	(73.4)	17.5	17.5	

[Yen]

Exchange rate	Q1 FY2021 average	Q1 FY2020 average	FY2021 planned
USD	109.76	107.38	110.00

Effect of fluctuations in exchange rate for FY2020 Q1: Revenue increased by ¥0.9 bn. and core operating profit decreased by ¥0.9 bn.

(2) Sales Revenue of Main Products

[Billion yen]

	Q1 FY2021	Comparison to previous year			Comparison to Forecasts	
		Q1 FY2020	Increase (decrease)	Change %	Forecasts*1	Change %
Domestic ethical drugs	74.5	73.3	1.3	1.7	286.3	26.0
Priority products	38.9	33.4	5.5	16.4	146.6	26.5
Stelara	11.4	7.0	4.5	64.0	42.7	26.7
Simponi	11.1	10.7	0.4	4.0	41.2	26.9
Tenelia	3.8	4.1	(0.3)	(6.4)	14.4	26.7
Canaglu	3.0	2.5	0.5	18.3	10.1	29.7
Canalia	2.5	2.5	(0.1)	(2.5)	9.3	26.5
Vafseo	0.1	-	0.1	-	1.3	6.1
Lexapro	3.9	3.9	0.1	1.9	14.1	28.1
Uplizna	0.1	-	0.1	-	1.4	9.3
Rupafin	1.9	1.7	0.2	12.3	8.9	21.0
Imusera	1.1	1.1	(0.0)	(1.7)	3.3	32.8
Vaccines	6.2	7.5	(1.3)	(17.1)	37.0	16.8
Influenza vaccine	(0.0)	(0.0)	0.0	-	14.3	(0.0)
Tetrabik	2.6	2.7	(0.1)	(3.8)	10.8	23.9
Mearubik	1.9	1.9	(0.0)	(1.0)	5.7	33.1
Varicella vaccine	1.1	1.3	(0.1)	(11.6)	4.1	27.1
JEBIK V	0.3	1.4	(1.1)	(76.0)	1.3	27.7
Long-listed drugs, etc.	29.4	32.3	(2.9)	(9.0)	102.7	28.6
Remicade	10.4	11.9	(1.4)	(12.2)	36.5	28.6
Overseas ethical drugs	14.4	12.6	1.7	13.8	100.6	14.3
Radicava ³	6.3	5.6	0.8	13.7	19.8	32.0
Royalty revenue, etc.	4.3	3.8	0.6	15.7	12.3	35.3
Royalty from INVOKANA	1.9	2.0	(0.2)	(9.1)	Undisclosed	-
Royalty from GILENYA ⁴	1.1	1.1	0.0	2.6	Undisclosed	-

*1: Announced on May 12, 2021

*2: Brackets indicate expense and loss

*3: Forecast of 19.8 was corrected from 19.2 announced on May 12, 2021.

*4: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

2. Financial Statement

(1) Balance Sheet

[Billion yen]

	End of Q1 FY2021	End of FY2020	Increase (decrease)	Notes
Assets	1,049.0	1,053.3	(4.3)	
Non-current assets	379.8	378.4	1.4	
Property, plant and equipment	83.5	82.1	1.4	Obtain 4.0, depreciation (2.6) etc.
Goodwill	90.7	90.6	0.1	
Intangible assets	92.3	91.1	1.2	
Other non-current assets	113.4	114.7	(1.3)	
Current assets	669.2	674.8	(5.7)	
Inventories	80.9	81.7	(0.8)	
Trade and other receivables	117.5	116.0	1.5	
Other financial assets	329.0	330.1	(1.1)	
Cash and cash equivalents	111.5	114.2	(2.7)	Refer to "(2) Cash Flow Statement"
Other current assets	30.2	32.8	(2.6)	
Liabilities	236.4	236.4	(0.0)	
Non-current liabilities	115.5	108.6	7.0	
Other non-current liabilities	84.9	77.5	7.4	
Other	30.6	31.1	(0.5)	
Current liabilities	120.8	127.8	(7.0)	
Trade and other payables	30.7	29.5	1.1	
Other	90.2	98.3	(8.1)	
Equity	812.6	816.9	(4.2)	
Share capital	50.0	50.0	-	
Capital surplus	448.0	448.0	-	
Retained earnings	312.2	313.3	(1.1)	
Other components of equity	2.5	5.6	(3.1)	

(2) Cash Flow Statement

[Billion yen]

	Q1 FY2021	Q1 FY2020	Increase (decrease)
Cash and cash equivalents at beginning of year	114.2	83.1	31.2
Cash flows from operating activities	10.5	0.9	9.6
Profit before tax	6.1	17.8	(11.8)
Depreciation and amortization	3.6	3.7	(0.1)
Loss (Gain) on sales of Property, Plant and Equipment	-	(8.1)	8.1
Trade receivable and payable	(0.4)	(0.7)	0.3
Other	1.2	(11.9)	13.1
Cash flows from investing activities	(5.2)	17.5	(22.7)
Purchase (proceeds from sales) of property, plant and equipment	(5.6)	8.1	(13.7)
Purchase (Proceeds from sales) of investments	2.8	64.7	(61.9)
Increase in deposits	(0.1)	(60.0)	59.9
Other	(2.3)	4.8	(7.1)
Cash flows from financing activities	(8.2)	(0.7)	(7.4)
Effect of exchange rate changes on cash and cash equivalents	0.2	(0.0)	0.2
Net increase(decrease) in cash and cash equivalents	(2.7)	17.7	(20.4)
Cash and cash equivalents at the end of period	111.5	100.7	10.8

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

occurring basis	Q1 FY2021	Q1 FY2020	Increase (decrease)
Investment in property, plant and equipment	4.0	5.6	(1.6)
Investment in information systems	0.6	0.3	0.3

(4) Depreciation and Amortization Costs

[Billion yen]

	Q1 FY2021	Q1 FY2020	Increase (decrease)
Property, plant and equipment	2.6	2.8	(0.3)
Intangible assets	0.3	0.3	0.0
Intangible assets with products	0.7	0.6	0.1

(1) Consolidated Forecasts of Profit and Loss

[Billion yen]

	FY2021 forecasts ^{*1}	Comparison to previous year			Notes [Y-on-Y Comparison]
		FY2020 actual	Increase (decrease)	Change %	
Revenue	407.5	377.8	29.7	7.9	Refer to "(2) Sales Revenue Forecasts for Main Products"
Domestic	296.1	313.0	(17.0)	(5.4)	
Overseas	111.4	64.8	46.7	72.1	
Overseas sales ratio	27.3%	17.1%			
Cost of sales	192.5	190.4	2.1	1.1	Increase due to the influence of NHI price revision, etc.
Sales cost ratio	47.2%	50.4%			
Gross profit	215.0	187.4	27.6	14.7	
SG&A expenses, etc.	189.0	166.4	22.6	13.6	Increase due to preparation costs for launch of global products, despite efforts in cost reduction for business productivity reform
R&D expenses	85.0	72.6	12.4	17.2	
Core operating profit	26.0	21.0	5.0	23.6	
Non-recurring items*2	4.0	(79.6)	83.6	-	
Operating profit*2	30.0	(58.5)	88.5	-	
Net profit attributable to owners of the Company*2	17.5	(46.9)	64.4	-	

Exchange rate

[Yen]

	FY2021 planned	FY2020 average
USD	110.00	105.94

(2) Sales Revenue Forecasts for Main Products

[Billion yen]

	FY2021 forecasts ^{*1}	Comparison to previous year		
		FY2020 actual	Increase (decrease)	Change %
Domestic ethical drugs	286.3	304.7	(18.3)	(6.0)
Priority products	146.6	137.7	9.0	6.5
Stelara	42.7	32.2	10.5	32.4
Simponi	41.2	42.3	(1.1)	(2.7)
Tenelia	14.4	15.1	(0.7)	(4.6)
Canaglu	10.1	10.3	(0.2)	(2.1)
Canalia	9.3	9.7	(0.4)	(4.2)
Vafseo	1.3	0.3	1.0	278.5
Lexapro	14.1	15.3	(1.3)	(8.2)
Uplizna	1.4	-	1.4	-
Rupafin	8.9	8.2	0.7	9.0
Imusera	3.3	4.1	(0.8)	(19.7)
Vaccines	37.0	42.6	(5.6)	(13.1)
Influenza vaccine	14.3	14.4	(0.1)	(0.8)
Tetrabik	10.8	10.9	(0.2)	(1.5)
Mearubik	5.7	6.1	(0.5)	(7.5)
Varicella vaccine	4.1	5.0	(0.8)	(16.8)
JEBIK V	1.3	5.2	(3.9)	(75.8)
Long-listed drugs, etc.	102.7	124.4	(21.7)	(17.5)
Remicade	36.5	45.4	(8.8)	(19.4)
Overseas ethical drugs	100.6	50.2	50.4	100.3
Radicava ^{*3}	19.8	22.0	(2.1)	(9.8)
Royalty revenue, etc.	12.3	15.9	(3.6)	(22.6)
Royalty from INVOKANA	Undisclosed	9.1	-	-
Royalty from GILENYA ^{*4}	Undisclosed	4.3	-	-

*1: Announced on May 12, 2021

*2: Brackets indicate expense and loss

*3: Forecast of 19.8 was corrected from 19.2 announced on May 12, 2021.

*4: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

(1) Profit and Loss

[Billion yen]

	FY2020					FY2021	
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year Actual	Q1 Apr. to Jun.	Full-year Forecasts
Revenue	91.8 24.3%	95.5 25.3%	102.9 27.2%	87.6 23.2%	377.8 100.0%	95.4 23.4%	407.5 100.0%
Domestic	75.7 24.2%	79.3 25.3%	86.7 27.7%	71.3 22.8%	313.0 100.0%	77.0 26.0%	296.1 100.0%
Overseas	16.1 24.8%	16.2 25.1%	16.1 24.9%	16.3 25.2%	64.8 100.0%	18.4 16.5%	111.4 100.0%
Cost of sales	45.6	49.2	52.4	43.2	190.4	47.6	192.5
Sales cost ratio	49.7%	51.6%	50.9%	49.3%	50.4%	49.9%	47.2%
Gross profit	46.2 24.7%	46.3 24.7%	50.5 26.9%	44.4 23.7%	187.4 100.0%	47.7 22.2%	215.0 100.0%
SG&A expenses, etc.	36.6 22.0%	41.3 24.8%	40.3 24.2%	48.1 28.9%	166.4 100.0%	41.9 22.2%	189.0 100.0%
R&D expenses	15.3 21.1%	18.6 25.6%	16.4 22.6%	22.3 30.7%	72.6 100.0%	18.8 22.1%	85.0 100.0%
Core operating profit*	9.6 45.5%	5.0 23.7%	10.2 48.4%	(3.7) (17.6%)	21.0 100.0%	5.8 22.4%	26.0 100.0%
Operating profit*	17.7 -	(79.6) -	7.2 -	(3.8) -	(58.5) -	5.8 19.3%	30.0 100.0%
Net profit attributable to owners of the Company*	11.5 -	(62.4) -	5.6 -	(1.6) -	(46.9) -	3.1 17.5%	17.5 100.0%

Note: The progress rates show in the lower of each cell, except for "cost of sales".

*Brackets indicate loss

(2) Sales Revenue of Main Products

[Billion yen]

	FY2020					FY2021	
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full-year actual	Q1 Apr. to Jun.	Full-year Forecasts
Domestic ethical drugs	73.3 24.0%	77.0 25.3%	84.7 27.8%	69.7 22.9%	304.7 100.0%	74.5 26.0%	286.3 100.0%
Priority products	33.4 24.3%	33.0 24.0%	37.3 27.1%	33.9 24.7%	137.7 100.0%	38.9 26.5%	146.6 100.0%
Stelara	7.0 21.6%	7.0 21.7%	9.1 28.1%	9.2 28.6%	32.2 100.0%	11.4 26.7%	42.7 100.0%
Simponi	10.7 25.2%	10.5 24.9%	11.5 27.3%	9.6 22.7%	42.3 100.0%	11.1 26.9%	41.2 100.0%
Tenelia	4.1 27.2%	3.9 25.6%	3.9 25.6%	3.3 21.6%	15.1 100.0%	3.8 26.7%	14.4 100.0%
Canaglu	2.5 24.6%	2.5 24.3%	3.0 28.6%	2.3 22.5%	10.3 100.0%	3.0 29.7%	10.1 100.0%
Canalia	2.5 26.1%	2.5 25.4%	2.5 25.4%	2.2 23.1%	9.7 100.0%	2.5 26.5%	9.3 100.0%
Vafseo	- -	0.3 88.1%	0.0 7.3%	0.0 4.7%	0.3 100.0%	0.1 6.1%	1.3 100.0%
Lexapro	3.9 25.3%	3.7 24.4%	4.2 27.7%	3.5 22.6%	15.3 100.0%	3.9 28.1%	14.1 100.0%
Uplizna	- -	- -	- -	- -	- -	0.1 9.3%	1.4 100.0%
Rupafin	1.7 20.4%	1.6 19.0%	2.0 24.4%	3.0 36.2%	8.2 100.0%	1.9 21.0%	8.9 100.0%
Imusera	1.1 26.8%	1.0 25.3%	1.1 27.1%	0.9 20.9%	4.1 100.0%	1.1 32.8%	3.3 100.0%
Vaccines	7.5 17.6%	13.6 31.9%	14.8 34.8%	6.7 15.6%	42.6 100.0%	6.2 16.8%	37.0 100.0%
Influenza vaccine	(0.0) (0.2%)	6.4 44.1%	7.5 52.0%	0.6 4.1%	14.4 100.0%	(0.0) (0.0%)	14.3 100.0%
Tetrabik	2.7 24.5%	2.5 22.6%	3.0 27.7%	2.8 25.3%	10.9 100.0%	2.6 23.9%	10.8 100.0%
Mearubik	1.9 30.9%	1.8 29.5%	1.4 22.2%	1.1 17.3%	6.1 100.0%	1.9 33.1%	5.7 100.0%
Varicella vaccine	1.3 25.5%	1.2 24.8%	1.3 26.1%	1.2 23.6%	5.0 100.0%	1.1 27.1%	4.1 100.0%
JEBIK V	1.4 27.9%	1.5 28.4%	1.4 27.5%	0.8 16.1%	5.2 100.0%	0.3 27.7%	1.3 100.0%
Long-listed drugs, etc.	32.3 26.0%	30.4 24.5%	32.6 26.2%	29.1 23.4%	124.4 100.0%	29.4 28.6%	102.7 100.0%
Remicade	11.9 26.2%	11.5 25.4%	12.1 26.6%	9.9 21.7%	45.4 100.0%	10.4 28.6%	36.5 100.0%
Overseas ethical drugs	12.6 25.2%	12.5 24.9%	11.9 23.7%	13.2 26.3%	50.2 100.0%	14.4 14.3%	100.6 100.0%
Radicava*1	5.6 25.4%	5.5 25.0%	4.9 22.1%	6.0 27.4%	22.0 100.0%	6.3 32.0%	19.8 100.0%
Royalty revenue, etc.	3.8 23.6%	4.1 25.6%	4.6 29.0%	3.5 21.8%	15.9 100.0%	4.3 35.3%	12.3 100.0%
Royalty from INVOKANA	2.0 22.5%	2.5 27.8%	2.8 31.2%	1.7 18.6%	9.1 100.0%	1.9 -	Undisclosed -
Royalty from GILENYA*2	1.1 24.5%	0.9 20.5%	1.2 26.8%	1.2 28.1%	4.3 100.0%	1.1 -	Undisclosed -

Note: The each figure in the lower displays the progress rate.

*1: Forecast of 19.8 was corrected from 19.2 announced on May 12, 2021.

*2: MTPC is currently in the arbitration proceedings with Novartis, and among the GILENYA Royalty amounts that MTPC is going to receive from Novartis, MTPC decided not to recognize some of those amounts as our revenue for FY2018 because such payments do not satisfy one of the requirements under IFRS15. The same accounting treatment will be continued during the period of the arbitration proceedings. Regardless of the disclosed amounts, MTPC maintains it is entitled to receive the full royalty amounts due according to the 1997 License Agreement with Novartis, and MTPC will rigorously pursue its rights in the arbitration.

5 Five-Year Financial Data

(Amounts less than ¥100 million are rounded)

(1) Profit and Loss

[Billion yen]

	FY2017	FY2018	FY2019	FY2020	Q1 FY2021	FY2021 forecasts
Revenues	433.9	424.8	379.8	377.8	95.4	407.5
Cost of sales	169.8	180.6	181.0	190.4	47.6	192.5
Gross profit	264.1	244.1	198.8	187.4	47.7	215.0
SG&A expenses, etc.	185.6	188.3	179.7	166.4	41.9	189.0
R&D expenses	79.1	86.5	79.4	72.6	18.8	85.0
Core operating profit	78.5	55.8	19.1	21.0	5.8	26.0
Operating profit	77.3	50.3	(6.1)	(58.5)	5.8	30.0
Net profit attributable to owners of the Company	58.0	37.4	0.1	(46.9)	3.1	17.5

(2) Balance Sheet

[Billion yen]

	End of FY2017	End of FY2018	End of FY2019	End of FY2020	End of Q1 FY2021
Assets	1,048.4	1,056.3	1,046.3	1,053.3	1,049.0
Non-current assets	462.9	467.9	452.8	378.4	379.8
Current assets	585.5	588.4	593.5	674.8	669.2
Liabilities	153.6	146.0	188.4	236.4	236.4
Non-current liabilities	55.4	54.3	90.3	108.6	115.5
Current liabilities	98.2	91.7	98.0	127.8	120.8
Equity	894.8	910.3	857.9	816.9	812.6

(3) Other Financial Data

[Billion yen]

	FY2017	FY2018	FY2019	FY2020	Q1 FY2021	FY2021 forecasts
Cash flows from operating activities	66.9	41.5	49.4	67.8	10.5	-
Cash flows from investing activities	(19.2)	(31.2)	(39.2)	(31.9)	(5.2)	-
Cash flows from financing activities	(32.5)	(25.9)	(37.9)	(7.2)	(8.2)	-
Investments in property, plant and equipment	6.2	8.6	15.5	20.0	4.5	15.7
Depreciation and Amortization Costs	11.5	11.5	10.9	15.2	3.6	13.6
Property, plant and equipment	7.6	7.1	7.0	11.1	2.6	9.8
Intangible assets including intangible assets with products	4.0	4.4	4.0	4.1	1.0	3.8
Ratio of equity attributable to owners of the Company to total assets [%]	84.2	85.0	81.4	76.9	77.0	-
ROE [%]	6.6	4.2	0.0	(5.6)	-	-
Basic earnings per share [¥]	103.35	66.64	0.26	(83.58)	-	-
Equity attributable to owners of the Company per share [¥]	1,574.26	1,600.64	1,519.22	1,443.99	1,438.95	-

(4) Number of Employees

	End of FY2017	End of FY2018	End of FY2019	End of FY2020	End of Q1 FY2021	Forecasts for end of FY2021
Consolidated	7,187	7,228	6,987	6,728	6,756	7,100
Non-consolidated	4,222	4,111	3,764	3,383	3,317	3,420

6 State of New Product Development (As of July 26, 2021)

(1) Central nervous system

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Asia Filed	In-house
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Bipolar disorder)	Asia Filed	Licensed from Gedeon Richter (Hungary)
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (Neuromyelitis optica spectrum disorder: NMOSD)	Asia Filed	Licensed from Horizon Therapeutics (Ireland)
	(Myasthenia gravis)	Japan Phase 3	Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Japan Filed (Apr. 2021)	Licensed from Neurocrine Biosciences (US)
		Asia Filed	
MT-210 (Roluperidone)	5-HT2A/Sigma 2 receptor antagonist (Schizophrenia)	US, Europe Phase 3	Licensed to Minerva Neurosciences (US)
ND0612 (Levodopa/Carbidopa)	Continuous SC pump (Parkinson's disease)	Global Phase 3	In-house
MT-1186 (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS / Oral suspension)	Global Phase 3	In-house
MT-8554 (Elismetrep)	TRPM8 antagonist (Painful diabetic peripheral neuropathy)	Europe Phase 2	In-house
	(Vasomotor symptoms associated with menopause)	Global Phase 2	
MT-3921	Anti-RGMA antibody (Spinal cord injury)	Phase 1	Co-developed with Osaka University (Japan)

(2) Immuno-inflammation

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MT-5547 (Fasimumab)	Fully human anti-NGF monoclonal antibody (Osteoarthritis)	Japan Phase 2/3	Licensed from Regeneron (US)
MT-7117 (Dersimelagon)	Selective melanocortin 1 receptor agonist (Erythropoietic protoporphyria, X-Linked protoporphyria)	Global Phase 3	In-house
	(Systemic sclerosis)	Global Phase 2	
MT-0551 (Inebilizumab)	Humanized anti-CD19 monoclonal antibody (IgG4-related disease)	Japan Phase 3	Licensed from Horizon Therapeutics (Ireland) and co-developed (Global study ongoing)
MT-2990	Fully human anti-interleukin-33 (IL-33) monoclonal antibody (Endometriosis)	Global Phase 2	In-house

※ Asia: Excluding Japan and China

(3) Vaccines

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MT-2355	Combined vaccine (Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants)	Japan Phase 3	Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)
MT-2271	Plant-based VLP vaccine (Prophylaxis of seasonal influenza/adults)	Canada Filed (Sep. 2019)	Medicago product (Canada)
	(Prophylaxis of seasonal influenza/elderly)	Europe Phase 3	
MT-2766	Plant-based VLP vaccine (Prophylaxis of COVID-19)	Global Phase 3	Medicago product (Canada)
MT-8972	Plant-based VLP vaccine (Prophylaxis of H5N1 influenza)	Canada Phase 2	Medicago product (Canada)
MT-7529	Plant-based VLP vaccine (Prophylaxis of H7N9 influenza)	Phase 1	Medicago product (Canada)
MT-5625	Plant-based VLP vaccine (Prophylaxis of rotavirus gastroenteritis)	Phase 1	Medicago product (Canada)
MT-2654	Adjuvanted plant-based VLP vaccine (Prophylaxis of seasonal influenza/elderly)	Phase 1	Medicago product (Canada)

(4) Others

Development code Product name (Generic name)	Category (Indications)	Region Stage	Origin/Licensee
MP-513 Tenelia (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Asia Filed	In-house
		China Filed (Sep. 2019)	
TA-7284 Canaglu/INVOKANA (Canagliflozin)	SGLT2 inhibitor (Diabetic nephropathy)	Japan Phase 3	In-house
MT-4580 Orkedia (Evocalcet)	Ca sensing receptor agonist (Secondary Hyperparathyroidism)	China, Asia Phase 3	Licensed to Kyowa Kirin (Japan)
MT-2765	Renin inhibitor (Hypertension)	China Phase 3	Licensed to Shanghai Pharmaceuticals (China)
MT-8633/TR1801-ADC	Anti-c-Met ADC* (Solid tumor)	Phase 1	In-house Collaborate with Open Innovation Partners (Japan)

*Antibody drug conjugate

※ Asia: Excluding Japan and China

Changes Since Previous Announcement

Development code Product name (Generic name)	Category (Indications)	Previous Announcement	As of July 26, 2021	Origin/Licensee
MCI-186 Radicut/Radicava (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis: ALS)	Asia Filed	Thailand Approved (Apr. 2021)	In-house
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Asia Filed	Indonesia Approved (July 2021)	Licensed from Gedeon Richter (Hungary)
	(Bipolar disorder)	None	Asia Filed	
MT-5199 (Valbenazine)	Vesicular monoamine transporter type 2 inhibitor (Tardive dyskinesia)	Asia Filed	Singapore Approved (May 2021)	Licensed from Neurocrine Biosciences (US)
MT-2765	Renin inhibitor (Hypertension)	None	China Phase 3	Licensed to Shanghai Pharmaceuticals (China)
MT-3995 (Apararenone)	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe Phase 2	Deleted (Discontinued)	In-house
		Japan Phase 2		
	(Non-alcoholic steatohepatitis: NASH)	Japan Phase 2		

※ Asia: Excluding Japan and China